Clinical Trial Update: Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating cemiplimab with or without fianlimab following Y-90 radioembolization in patients with hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Cemiplimab (cemiplimab)
• Fianlimab (fianlimab)

Snippet

Sponsor: Virginia Commonwealth University | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: NOT_YET_RECRUITING